• No results found

University of Groningen Quality of prescribing in chronic kidney disease and type 2 diabetes Smits, Kirsten Petronella Juliana

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Quality of prescribing in chronic kidney disease and type 2 diabetes Smits, Kirsten Petronella Juliana"

Copied!
5
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Quality of prescribing in chronic kidney disease and type 2 diabetes

Smits, Kirsten Petronella Juliana

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Smits, K. P. J. (2018). Quality of prescribing in chronic kidney disease and type 2 diabetes. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)
(3)
(4)

Curriculum vitae

257

C

Kirsten Smits was born on August 17th, 1989 in Steinheim, Germany. After

finish-ing secondary school in 2007, she started her study, Nutrition and Health at the Wageningen University. In 2011, she obtained her Bachelor’s degree and contin-ued with a master Nutrition and Health specialising in Epidemiology and Public Health at the Wageningen University. During her master program, she wrote her master thesis focusing on the association of fish fatty acids with cardiovascular disease in healthy people, patients with prior myocardial infarction and patients with diabetes. In 2012, she travelled to Pittsburgh, United States of America for an internship of 6 months at Pittsburgh University. There she studied the relation between vitamin E and vitamin C with coronary artery disease and haptoglobin genotype in diabetes patients. She obtained her masters degree in 2013.

From March 2014 to August 2017, she worked as a PhD candidate at the depart-ment of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen. Her PhD-project focused on developing and validating prescribing quality indicators to assess the quality of chronic kidney disease and diabetes type 2 care.

Since October 2017, she works as a postdoctoral researcher at the department of Quality and Safety of Oral Health Care at the Radboud university medical center. Her work is focused on quality indicators for assessing quality of oral health care, as well as finding links between nutritional aspects and oral health and patient perceptions of integrated health care.

(5)

Referenties

GERELATEERDE DOCUMENTEN

The newly developed PQIs, including the clinical action indicators, have been developed and defined in such a way that they can be implemented in quality improvement initiatives

The selected PQIs were three indicators on current prescribing of statins and RAAS inhibitors when recommended and four PQIs on potential inappropriate

Tijdens de ontwikkeling zijn verscheidene indicatoren verworpen, zoals de volume-indicatoren over het gebruik van bloedglucose-ver- lagende middelen en de

· The percentage of patients with CrCl <60 ml/min that is non-adherent to the diabetes treatment since the patient received more than 120% or less than 80% of the

10 percentage points for the medication need and medication choice indicators and at 5 percentage points for safety indicators with outcome >5% or 1 percent- age point for

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded

(1B.) The percentage of patients with T2D between 18 and 55 years that reached the target level for HbA 1c (≤53 mmol/mol) with glucose lowering drugs.. 8- 5.5- 8+ 9+

Table S6.1: Definition of comorbidities, which were documented in the medical records by means of the ICPC or short text prescriptions which were manually coded in GIANTT.